TY - JOUR
T1 - Marked Reduction in the Number of Platelet—Tritiated Imipramine Binding Sites in Geriatric Depression
AU - Nemeroff, Charles B.
AU - Knight, David L.
AU - Krishnan, K. Ranga R.
AU - Slotkin, Theodore A.
AU - Bissette, Garth
AU - Melville, Mary Lou
AU - Blazer, Dan G.
PY - 1988/10
Y1 - 1988/10
N2 - The number (B(max)) and affinity (K(d)) of platelet-tritiated imipramine binding sites was determined in young and middle-aged controls 50 years of age and younger (n = 25), elderly normal controls over 60 years of age (n = 18), patients who fulfilled DSM-III criteria for major depression who were under 50 years of age (n = 29), patients who fulfilled DSM-III criteria for major depression who were 60 years of age and older (n = 19), and patients who fulfilled both DSM-III criteria for primary degenerative dementia and National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria for probable Alzheimer's disease (n = 13). Both groups of depressed patients (under 50 and over 60 years of age) exhibited significant reductions (↓ 42%) in the number of platelet-tritiated imipramine binding sites with no change in affinity, when compared with their age-matched controls. There was little overlap in B(max) values between the elderly depressed patients and their controls. The patients with probable Alzheimer's disease showed no alteration in platelet-tritiated imipramine binding. There was no statistically significant relationship between postdexamethasone plasma cortisol concentrations and tritiated imipramine binding. These results indicate that platelet-tritiated imipramine binding may have potential utility as a diagnostic adjunct in geriatric depression, and moreover that the reduction in the number of platelet-tritiated imipramine binding sites is not due to hypercortisolemia.
AB - The number (B(max)) and affinity (K(d)) of platelet-tritiated imipramine binding sites was determined in young and middle-aged controls 50 years of age and younger (n = 25), elderly normal controls over 60 years of age (n = 18), patients who fulfilled DSM-III criteria for major depression who were under 50 years of age (n = 29), patients who fulfilled DSM-III criteria for major depression who were 60 years of age and older (n = 19), and patients who fulfilled both DSM-III criteria for primary degenerative dementia and National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria for probable Alzheimer's disease (n = 13). Both groups of depressed patients (under 50 and over 60 years of age) exhibited significant reductions (↓ 42%) in the number of platelet-tritiated imipramine binding sites with no change in affinity, when compared with their age-matched controls. There was little overlap in B(max) values between the elderly depressed patients and their controls. The patients with probable Alzheimer's disease showed no alteration in platelet-tritiated imipramine binding. There was no statistically significant relationship between postdexamethasone plasma cortisol concentrations and tritiated imipramine binding. These results indicate that platelet-tritiated imipramine binding may have potential utility as a diagnostic adjunct in geriatric depression, and moreover that the reduction in the number of platelet-tritiated imipramine binding sites is not due to hypercortisolemia.
UR - http://www.scopus.com/inward/record.url?scp=0023737084&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023737084&partnerID=8YFLogxK
U2 - 10.1001/archpsyc.1988.01800340045006
DO - 10.1001/archpsyc.1988.01800340045006
M3 - Article
C2 - 2844132
AN - SCOPUS:0023737084
VL - 45
SP - 919
EP - 923
JO - JAMA Psychiatry
JF - JAMA Psychiatry
SN - 2168-622X
IS - 10
ER -